title: Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease.
abstract: The effect of coinfection with hepatitis C virus (HCV) on immune restoration in 39 human immunodeficiency virus (HIV)-infected patients during treatment with combined antiretroviral therapy (cART) was prospectively evaluated. After 48 weeks of treatment, HCV-coinfected patients had lower increases in CD4% (P = .05), total CD4+ (P = .01), and naïve CD4+ (P = .06) T cells than did single-infected subjects. Higher baseline naïve CD4+ T-cell levels were associated with better CD4+ (P = .05) and naïve CD4+ (P < .001) T-cell recovery. After a 4-year follow up, the differences disappeared (median CD4+ increase: 291 and 306 cells for HCV-positive and HCV-negative patients, respectively, P = .9). No significant differences were seen in memory CD4+ T cells (P = .30), and CD8+ cells expressing CD38 (P = .10) and CD28 (P = .73). These results suggest that, independently of other factors, infection with HCV blunts early CD4+ T-cell recovery in HIV-infected patients treated with combined antiretroviral therapy (cART). However, as good control of viral replication is maintained, satisfactory long-term immune restoration can nonetheless be achieved.
authors.affiliation: Department of Infectious Diseases, IDIBELL, Hospital Universitari de Bellvitge, University of Barcelona, C/ Feixa Llarga s/n, 08907, L'Hospitalet, Barcelona, Spain. msantin@csub.scs.es
authors.forename: M
authors.initials: M
authors.lastname: Santin
authors.forename: M
authors.initials: M
authors.lastname: Mestre
authors.forename: E
authors.initials: E
authors.lastname: Shaw
authors.forename: M J
authors.initials: MJ
authors.lastname: Barbera
authors.forename: A
authors.initials: A
authors.lastname: Casanova
authors.forename: J
authors.initials: J
authors.lastname: Niubo
authors.forename: F
authors.initials: F
authors.lastname: Bolao
authors.forename: D
authors.initials: D
authors.lastname: Podzamczer
authors.forename: F
authors.initials: F
authors.lastname: Gudiol
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000276:immunology; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018106:CD28 Antigens / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000276:immunology*; D016174:Hepacivirus / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000276:immunology* / Q000821:virology; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000276:immunology / Q000821:virology*; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000235:genetics; D014779:Virus Replication / Q000235:genetics
chemical_list: D018106:CD28 Antigens; D012367:RNA, Viral; D051997:ADP-ribosyl Cyclase 1